linjc16/ctgov huggingface dataset:
Dissecting the Biology of Early-onset Colorectal Cancer

Study Overview
=================
Brief Summary
-----------------
Contrarily to late-onset (LO) colorectal cancer (CRC), early-onset (EO) CRC incidence is increasingly growing. Several factors, such as obesity, chronic inflammation, and intestinal dysbiosis, can increase the general risk of CRC. However, little is known about the biology of EO-CRC. To evaluate whether such selective rise in the incidence of EO-CRC patients mirrors a distinct transcriptomic profile, the investigators will first dissect EO-CRC's transcriptomic landscape. Then, the investigators will investigate the colorectal cancer stem cell (CSC) compartment by in vitro functional assays and RNA-seq analysis. Because our preliminary data indicate an increased aggressiveness of the tumor microenvironment (TME) in EO-CRC,the investigators propose to investigate the CSC niche and the interaction with the TME to dissect the molecular and cellular pathways occurring in EO-CRC. A cohort of 30 EO-CRC patients (<50 years old) will be enrolled and fully characterized. About 10 EO-CRC-derived CSCs in the form of organoids and spheroids will be generated. Since the relevant differences between CR-CSCs isolated from EO-CRC vs LO-CRC patients are still unknown, the investigators will gain information about their specific features such as clonogenic activity, tumorigenic/invasive capacity, and about differences in the mechanisms regulating their cross-talk with TME components.

Official Title
-----------------
Study of the Biology of Colorectal Cancer in Early-onset Patients

Conditions
-----------------
Colon Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 and < 50 years ; Written informed consent Exclusion Criteria: Non-availability of informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Isolation and characterization of EO-CRC-derived CSCs | Identification of EO-CRC-derived CSCs by cytofluorimetry and immunofluorescence analyses (Percentage of cells positive for CD133, CD24, CD44 and CD44v6 expression). | 2 years | 
| Identification of obesity-associated adipokines in EO-CRC obese patients | Elisa/Luminex assay evaluation of obesity-associated adipokines concentration | 2 years | 
| Identification of EO-CRC specific signatures and pathways | RNAseq data analysis of differentially expressed genes in EO-CRC-derived CSCs compared with LO-CRC-derived CSCs. | 2 years |
Looking At Triple Negative Breast Cancer Patient Experience Patterns in Medical Trials

Study Overview
=================
Brief Summary
-----------------
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical trials, both positive and negative. The goal is to identify the obstacles and challenges that prevent participation in Triple Negative Breast Cancer clinical trials, as well as the reasons for withdrawal or discontinuation. The insights gained from this study will ultimately benefit those with Triple Negative Breast Cancer who may be invited to participate in clinical research in the years to come.

Official Title
-----------------
Investigation of Patterns in Clinical Trial Experiences by Patients Participating in Triple Negative Breast Cancer Clinical Trials

Conditions
-----------------
Triple Negative Breast Cancer, Breast Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. Capable of giving signed informed consent, which includes compliance with requirements and restrictions listed in the informed consent form (ICF) and in the protocol Exclusion Criteria: Pregnant or lactating woman Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial Inability to perform regular electronic reporting

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of triple negative breast cancer patients who decide to enroll in a clinical study |  | 3 months | 
| Rate of triple negative breast cancer patients who remain in a clinical study to completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, triple negative breast cancer
An Observational Study of Patients With Chronic Liver Disease

Study Overview
=================
Brief Summary
-----------------
TARGET-Liver Disease (TARGET-LD) is an observational research study to conduct a comprehensive review of outcomes for patients with chronic liver disease (CLD).

Official Title
-----------------
An Observational Study of Patients With Chronic Liver Disease

Conditions
-----------------
Chronic Liver Disease, Cirrhosis

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Disease Cohort •Adult* patients at the time of enrollment with a diagnosis of CLD/cirrhosis by ICD-10 code in the EHR interface Engaged Cohort Adult* patients diagnosed and managed for CLD/cirrhosis invited to participate Ability to provide written informed consent Exclusion Criteria: Disease Cohort Death Manual removal (sponsor or site request) No EHR interface encounter > 3 years. Engaged Cohort Patient expressed desire to withdraw consent to complete PROs Failure to complete PROs within 24 weeks of initial invitation Greater than 24 months lapse of survey completion after baseline surveys completed Additionally, the criteria detailed for Disease Cohort apply to the Engaged Cohort.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Disease Cohort<br> | Other: Observational<br>* Observational<br>|
| Engaged Cohort<br> | Other: Observational<br>* Observational<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To characterize the natural history of disease in patients with CLD from various etiologies and Cirrhosis |  | 20 Years | 
| To assess safety and effectiveness of CLD/Cirrhosis treatments and treatments for complications of any chronic liver disease |  | 20 Years | 
| To establish learning health networks focused on quality of care for patients |  | 20 Years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate provider management practices in the treatment of patients with CLD/Cirrhosis |  | 20 Years | 
| To evaluate longitudinal and patient reported outcomes in CLD/Cirrhosis |  | 20 Years |
The Effect of LASIK on the Calibration of IOL Formula Calculation: a Comparative Study

Study Overview
=================
Brief Summary
-----------------
Direct comparison study between previous LASIK or non-LASIK cataract eyes, the performance between non-LASIK and LASIK patients were (i) Ophthalmic examinations: UDVA, CDVA and uncorrected near visual acuity (UNVA) (40cm) and (ii) Refractive prediction error: defined as difference between postoperative sphere and target refraction.

Official Title
-----------------
The Effect of LASIK on the Calibration of IOL Formula Calculation: a Comparative Study

Conditions
-----------------
Cataract Senile

Intervention / Treatment
-----------------
* Device: routine cataract surgery and intraocular lens implantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of cataract in both eyes corrected distance visual acuity under 20/40 Phacoemulsification cataract surgery was arranged for both eyes Exclusion Criteria: complicated cataract corneal opacities or irregularities corneal astigmatism > 1.50 diopter amblyopia, anisometropia surgical complications such as posterior capsular bag rupture or vitreous loss, IOL tilt or decentration coexisting ocular pathologies, glaucoma, non-dilating pupil, history of intraocular surgery, or retinopathy optic nerve or macular diseases refusal or unable to maintain follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| previous LASIK group<br> | Device: routine cataract surgery and intraocular lens implantation<br>* routine cataract surgery and intraocular lens implantation<br>|
| previous non-LASIK group<br> | Device: routine cataract surgery and intraocular lens implantation<br>* routine cataract surgery and intraocular lens implantation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual acuity |  | 1 month after surgery | 
| refractive prediction error |  | 1 month after surgery |
Food Survey, Curbside, Remote APPs SCFI

Study Overview
=================
Brief Summary
-----------------
The proposed research will create accurate and standardized household food waste measurement technologies that foster serial and longitudinal assessments as well as confident and convenient one-time measurement. The investigators propose the SCFI field study where participants simultaneously deploy 3 measurement approaches (1) retrospective surveys (2) curbside audits, and (3) the FoodImage smartphone app.

Official Title
-----------------
An Innovative, Accessible, and Flexible Approach for Household Food Waste Measurement - SCFI

Conditions
-----------------
Nutrition Sciences, Climate, Recycling, Waste Management

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female, age 18-64 years Willing and able to store household food waste for curbside pickup by a third-party waste pickup company Internet or Wi-Fi availability to complete online surveys Ownership of an IPhone 9s or later, operable Apple ID, password, and email address that they are willing and able to use to collect data during the study. Subject acknowledges data usage and associated charges are a result of study Willing to complete all study procedures and adhere to study visit timelines Exclusion Criteria: Not willing to adhere to study procedures and study visit timelines Any condition or circumstance that in the judgement of the PI could interfere with study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SCFI<br>SCFI participants will complete a survey once per week for three consecutive weeks. They will participate in training for the FoodImage app and deploy it the last two weeks of their study period. During these last two weeks, these participants will also have waste collected on designated days by a waste pickup contractor. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Household Food Waste | Weight | 1 week | 
| Household Food Waste | Energy (kcal) | 1 week |
Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients

Study Overview
=================
Brief Summary
-----------------
This research study aims to address the limited understanding of the challenges faced by specific demographic groups of chronic lymphocytic leukemia patients in their participation in clinical trials. This trial will scrutinize the experiences of patients diagnosed with chronic lymphocytic leukemia as they take part in a separate medical intervention clinical trial. The focus will be on tracking the rates of completion and withdrawal among these individuals. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future chronic lymphocytic leukemia patients.

Official Title
-----------------
Exploring Patient Experiences of Individuals Joining Chronic Lymphocytic Leukemia Clinical Trials

Conditions
-----------------
Chronic Lymphocytic Leukemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient has been diagnosed with chronic lymphocytic leukemia Patient is a minimum of 18 years or older Able to comprehend the investigational nature of the protocol and provide informed consent Exclusion Criteria: Pregnant or lactating women Patients who are currently receiving any other investigational drug Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of chronic lymphocytic leukemia patients who decide to join in a clinical study |  | 3 months | 
| Rate of patients who remain in an chronic lymphocytic leukemia clinical study to completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Lymphocytic Leukemia
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Study Overview
=================
Brief Summary
-----------------
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.

Official Title
-----------------
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.

Conditions
-----------------
Carcinoma, Pancreatic Ductal

Intervention / Treatment
-----------------
* Procedure: Selective extended dissection of pancreaticoduodenectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery. 2) Patients received radical surgery (R0) and had complete photos or videos of the operation. Exclusion Criteria: - 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection. 2) Patients with incomplete clinical, pathological, imaging and follow-up information.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Selective extended dissection (SED) group<br> | Procedure: Selective extended dissection of pancreaticoduodenectomy<br>* An optimized procedure of pancreaticoduodenectomy which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor.<br>|
| Standard dissection (SD) group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival (DFS) |  | From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months. |
Room Air a Safe Alternative to Dye Injection in Ureterography

Study Overview
=================
Brief Summary
-----------------
The procedure began in the Thirties .Retrograde pyelography is an essential step in most endoscopic procedure. This procedure is used as an investigation, with different indication in the past and the present, to delineate the ureter and pelvicalyceal system either before or after the operation, for example to detect any complication as a perforation and the need for stent placement. The procedure has an alternative, less invasive, the IVP. Multiple articles explored the use of air in the puncture of PCNL and to identify the posterior calyx, but to our knowledge there is no articles addressed the idea of air injection in the ureter. The greatest fear is air embolism or non-visualization of the ureter. The availability and cost of contrast material may be a problem, most urologist face

Detailed Description
-----------------
Our aim is to explore the feasibility of using Room air as a contrast material and check the safety of this procedure. Materials and methods: A pilot study in Assiut university hospital Urology department to evaluate the efficacy of air injection as a replacement dye injection in cases of endoscopy either in emergency or elective situation. Twenty patients were selected randomly, to evaluate the impact of retrograde pyelography (RPG) using air in cases of obstructed ureters and raised renal function.

Official Title
-----------------
Room Air vs Iohexol Injection in URS

Conditions
-----------------
Ureteral Obstruction

Intervention / Treatment
-----------------
* Diagnostic Test: air injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients undergoing Urs Exclusion Criteria: no
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients with obstructed ureters<br> | Diagnostic Test: air injection<br>* delination of the ureter and pelvis by injecting air under C-ARM<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| no air embolism |  | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification of ureter |  | intraoperative |
Taiwan Diabetes Registry

Study Overview
=================
Brief Summary
-----------------
To Investigate the Risk Factors, Life Style and Treatments of the Microvascular Disease，Macrovascular Disease and Neuropathy in Patients With Diabetes.

Detailed Description
-----------------
At the first year (2015), the patients ever enrolled into the quality control study by Taiwan Association of Diabetes Educators in 2006 and 2011 will be recruited, and their relevant clinical data will be regularly registered yearly until 2030. In addition, it is planned that type 1 diabetic patients will be enrolled, and their clinical data will be regularly recorded yearly until 2030. Also, newly diagnosed type 2 diabetic patients will be recruited, and their clinical data will be regularly entered to the diabetes web-based system yearly until 2030. We will also include pregnant patients with diabetes since 2023, and their data will be monitored and followed until 2030. Finally, we will also include pregnant patients with diabetes since 2023, and their data will be monitored and followed until 2030.

Official Title
-----------------
Taiwan Diabetes Registry (TDR)

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Observational study - registry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of diabetes mellitus Exclusion Criteria: Patients who do not have diabetes mellitus Participating in an interventional trial requiring informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observational study - registry|Observational study - registry|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Provide data on patient characteristics |  | Ten years | 
| Provide data on disease management. |  | Ten years |